Stay ahead with our blog, your go-to source for the latest in healthcare
technology, policy, and research.
Four Ways Pharmaceutical Companies Are De-Risking R&D with Real-World Data Pharmaceutical research and development is inherently complex and high-risk. Sponsors must ensure that investigational products demonstrate both strong therapeutic efficacy and an acceptable safety profile. At the same time, they must manage escalating costs, lengthy timelines, and increasing expectations from regulators, payers, and
Cancer affects everyone, including adolescents and young adults who are at increasing risk of developing certain types of disease. It’s a particularly challenging time of life to receive a cancer diagnosis. Many cancers in younger patients can be aggressive, and treatment can be complicated, expensive, painful, and isolating for young people who should be focused […]
…
3 key takeaways from ASCO 2025: Staying nimble in a changing environment The annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for oncology professionals, patient advocates, data experts, and industry representatives to come together and share the latest research in cancer care. This year, thousands of attendees descended on Chicago […]
…
How real-world data can tell the story of breast, ovarian and uterine cancers at a pivotal moment in women’s health Nearly 4 million women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in […]
…
Nearly 4 million women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in treatment and outcomes. Clinical trials have been helpful in illuminating some of these issues. And early approaches to leveraging real-world […]
…
Cancer comes in many forms, including hematologic malignancies that originate in blood-forming tissues or in the cells of the immune system, and solid tumors that form as abnormal masses of tissue and are named for the type of cells and classified by the organ or biologic structure from which they originate. Hematologic cancers, such as […]
…
Using AI to transform life sciences data analysis: An early look at CAILIN’s performance COTA has launched the COTA AI Language Insights Network (CAILIN) to expedite data analytics. CAILIN is an oncology trained, on-demand insight generator designed to answer a variety of fundamental questions pertaining to data analytics, including specific cohort size, subgroup breakdowns, […]
…
